157 related articles for article (PubMed ID: 35289092)
21. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
22. Decreased serum soluble programmed cell death ligand-1 level as a potential biomarker for missed miscarriage.
Li Q; Chen C; Wu J; Poon LC; Wang CC; Li TC; Zhang T; Guo X; Song L; Wang X; Zhang Q; Ye Z; Yang Y; Lu J; Yao J; Ye D; Wang Y
Hum Reprod; 2023 Nov; 38(11):2128-2136. PubMed ID: 37671597
[TBL] [Abstract][Full Text] [Related]
23. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization.
Odagiri N; Hai H; Thuy LTT; Dong MP; Suoh M; Kotani K; Hagihara A; Uchida-Kobayashi S; Tamori A; Enomoto M; Kawada N
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32722224
[TBL] [Abstract][Full Text] [Related]
24. Association of TIM-3 with BCLC Stage, Serum PD-L1 Detection, and Response to Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma.
Tampaki M; Ionas E; Hadziyannis E; Deutsch M; Malagari K; Koskinas J
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31952209
[TBL] [Abstract][Full Text] [Related]
25. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
[TBL] [Abstract][Full Text] [Related]
26. Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis: A systematic review.
Zhao Y; Cai G; Zhou L; Liu L; Qi X; Bai M; Li Y; Fan D; Han G
Asia Pac J Clin Oncol; 2013 Dec; 9(4):357-64. PubMed ID: 23714021
[TBL] [Abstract][Full Text] [Related]
27. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
[TBL] [Abstract][Full Text] [Related]
28. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
[TBL] [Abstract][Full Text] [Related]
30. Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.
Chen J; Zhang D; Yuan Y
Clin Exp Med; 2023 Jul; 23(3):579-590. PubMed ID: 36018466
[TBL] [Abstract][Full Text] [Related]
31. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
[TBL] [Abstract][Full Text] [Related]
32. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
Front Immunol; 2022; 13():913464. PubMed ID: 35677059
[TBL] [Abstract][Full Text] [Related]
33. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
34. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
[TBL] [Abstract][Full Text] [Related]
35. Effects of transarterial chemoembolization on the immunological function of patients with hepatocellular carcinoma.
Guo J; Wang S; Han Y; Jia Z; Wang R
Oncol Lett; 2021 Jul; 22(1):554. PubMed ID: 34084221
[TBL] [Abstract][Full Text] [Related]
36. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
37. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.
Peng Z; Chen S; Xiao H; Wang Y; Li J; Mei J; Chen Z; Zhou Q; Feng S; Chen M; Qian G; Peng S; Kuang M
Radiology; 2019 Jul; 292(1):237-247. PubMed ID: 31135299
[TBL] [Abstract][Full Text] [Related]
38. Changes in the Peripheral Blood Treg Cell Proportion in Hepatocellular Carcinoma Patients After Transarterial Chemoembolization With Microparticles.
Ren Z; Yue Y; Zhang Y; Dong J; Liu Y; Yang X; Lin X; Zhao X; Wei Z; Zheng Y; Wang T
Front Immunol; 2021; 12():624789. PubMed ID: 33717135
[TBL] [Abstract][Full Text] [Related]
39. Rationality and effectiveness of transarterial chemoembolization as an initial treatment for BCLC B stage HBV-related hepatocellular carcinoma.
Heng-jun G; Yao-jun Z; Min-shan C; Mei-xian C; Jun-ting H; Li X; Lau WY
Liver Int; 2014 Apr; 34(4):612-20. PubMed ID: 24028297
[TBL] [Abstract][Full Text] [Related]
40. Tumor Size Affects Efficacy of Adjuvant Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma and Microvascular Invasion.
Liu S; Li H; Guo L; Zhang B; Zhou B; Zhang W; Zhou J; Fan J; Ye Q
Oncologist; 2019 Apr; 24(4):513-520. PubMed ID: 30552155
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
